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tation. Methods: Patients with relapsed or refractory Hodgkin’s
disease received cyclophosphamide 4.5 g/m2 for mobilization che-
motherapy, following which they were given G-CSF 10 g/kg/day
subcutaneously until stem cell collection. Patients then received
cyclophosphamide 1.8 g/m2 from day6 to day3, etoposide 800
mg/m2from day 6 to day 4, and carmustine 200 mg/m2 on day
6 and day 5. Beginning on Day 0, G-CSF 5 g/kg/day was
administered. Patients with bulky disease at relapse or multiple (2
or more) recurrences in the same nodal basin(s) after primary or
salvage therapies were eligible to receive consolidative radiother-
apy. Results: 40 patients were enrolled in this study. Thirty-nine
underwent autologous transplantation, with a median age of 31.8
years (range 17.5–74.4 years). Fifteen (37.5%) patients had primary
refractory disease. The median times to neutrophil and platelet
count recovery were 9 and 14.5 days, respectively. Twenty-two
(55%) patients relapsed with a median time to progression of 0.98
years (range 0.2–8.7 years). Overall survival was 50% with a me-
dian follow up of 5.4 years (range 2–8.7 years). Four patients died
of transplant related causes. These were: pulmonary ﬁbrosis, adult
respiratory distress syndrome, myocardial infarction prior to un-
dergoing transplantation, and cryptogenic organizing pneumonitis
(BOOP). Conclusions: Cyclophosphamide, etoposide, and car-
mustine is an effective high dose chemotherapy regimen for the
treatment of relapsed and refractory Hodgkin’s disease. However,
many of these patients unfortunately relapse. Novel approaches to
reduce the risk of relapse such as post transplant immunotherapy
or allogeneic transplantation should be investigated in this patient
population.
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HIGH DOSE MITOXANTRONE AND MELPHALAN FOLLOWED BY AUTOL-
OGOUS STEM CELL TRANSPLANTATION FOR LYMPHOID MALIGNAN-
CIES
Chan, G.W.1, Sprague, K.A.1, Klein, A.K.1, Klingemann, H.G.1 Tufts-
New England Medical Center, Boston, MA.
We evaluated outcomes in 44 patients with lymphoid malig-
nancies who underwent autologous stem cell transplantation
following a preparative regimen of mitoxantrone 20 mg/m2 over
1 hour  3 (total dose 60 mg/m2 ) and melphalan 60 mg/m2
over 1 hour  3 (total dose 180 mg/m2). Twelve patients (6
male) had nodular sclerosing (n  9) or mixed cellularity (n 
3) Hodgkin’s Lymphoma (HL), while 32 patients (17 male) had
diffuse large B-cell (n  21), T-lymphoblastic (n  4), mantle
cell (n  2), T cell rich B-cell (n  1), or anaplastic large cell
(n  3) non-Hodgkin’s lymphoma (NHL). The median age
among Hodgkin’s patients was 35 years (range 19–46 years)
while the median age among NHL patients was 47 years (range
23–63 years). Two patients were in ﬁrst complete remission
(CR), 1 patient in CR2, while 15 patients had partial response,
14 patients had relapsed disease, and 12 patients had refractory
disease at the time of transplant. All patients had a left ventric-
ular ejection fraction of at least 40% at the time of transplant.
Mitoxantrone and melphalan were well tolerated, with grade 3/4
mucositis the most common toxicity. Neutrophil engraftment
was seen at the median of 13 days (range 8–34 days). Day 100
transplant related mortality (TRM) was 3%. The 3-year disease
free (DFS) and overall survival (OS) were 63% and 67%, re-
spectively. Three-year DFS were similar between HL and NHL
patients (67% vs 63%: P  .66). There was no signiﬁcant
difference in 3-year DFS between patients with CR or PR versus
relapsed or refractory disease (66% vs 62%: P  .96). DFS were
similar among all disease subtypes. Congestive heart failure
occurred in on 3 patients (7%). One patient died of complica-
tions from CHF while 2 others recovered cardiac function. In
conclusion, mitoxantrone and melphalan preparative regimen is
well tolerated with minimal cardiac toxicity in patients with
lymphoid malignancies previously treated with anthracyclines.
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DIVIDED DOSE SCHEDULING OF MESNA TO PREVENT THE DEVELOP-
MENT OF CYCLOPHOSPHAMIDE-ASSOCIATED HEMORRHAGIC CYSTITIS
IN AUTOLOGOUS TRANSPLANT PATIENTS
Mc Pheeters, L.3, Kennedy, D.3, Holmberg, L.A.1,2 1. Fred Hutchinson
Cancer Research Center, Seattle, WA; 2. University of Washington
School of Medicine, Department of Medicine, Seattle, WA; 3. University
of Washington School of Medicine, Department of Pharmaceutical Sci-
ences, Seattle, WA.
Cyclophosphamide is an alkylating anti-neoplastic agent used for
mobilization and transplant regimens in ASCT patients. Hemor-
rhagic cystitis (HC) is a possible adverse reaction associated with
cyclophosphamide and may be prevented by the concomitant use
of mesna and intravenous (IV) hydration. Several mesna dosing
schedules have been studied in non-transplant clinical settings;
however, few studies have included ASCT patients. In order to
facilitate administration of cyclophosphamide in the outpatient
setting, and to reduce hospitalizations for continuous bladder irri-
gation, the standard of care at our institution since January 2003
has been to give mesna IV at the same dose of cyclophosphamide
in four equally divided doses at 15 minutes before, then 3, 6, and
8 hours after the administration of cyclophosphamide. A retrospec-
tive review was performed in ASCT patients to evaluate the effec-
tiveness of this mesna dosing schedule with aggressive IV hydra-
tion in preventing the development of HC. Cyclophosphamide
dosing in mobilization regimens was 3–4 gm/m2 and in transplant
regimens was 60–120 mg/kg. Of the 64 patients evaluated, 35
(55%) developed hematuria according to NCI Common Toxicity
Criteria, v. 3.0. Only one patient developed symptomatic HC.
Four patients developed hematuria with concurrent urinary tract
infections. There were no statistical differences between the
groups who did or did not develop HC in terms of age, gender,
underlying malignancy, past medical history, and concurrent use of
medications that place a patient at increased hemorrhagic risk.
More patients developed hematuria after receiving cyclophospha-
mide in transplant regimens than after mobilization regimens (24
vs 11 patients, P  .05). Patients who previously received cyclo-
phosphamide or ifosfamide as conventional chemotherapy were
more likely to develop hematuria (P  .025) after mobilization or
conditioning regimens. Patients were more likely to develop he-
maturia after the transplant regimen if they had a prior history of
receiving cyclophosphamide or ifosfamide (P  .001) with conven-
tional or mobilization chemotherapy. In conclusion, mesna IV
given in four equally divided doses with aggressive IV hydration is
effective in preventing the development of signiﬁcant HC. Addi-
tionally, this regimen facilitated the routine outpatient administra-
tion of high-dose cyclophosphamide.
278
INTERLEUKIN 2 (IL-2) AND GRANULOCYTE-MACROPHAGE COLONY
STIMULATING FACTOR (SARGRAMOSTIN) (GM-CSF) FOLLOWING AU-
TOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANT (ASCT) FOR
BREAST CANCER
Holmberg, L.A.1,2,3, Bensinger, W.1,2,3 1. Fred Hutchinson Cancer
Research Center, Seattle, WA; 2. University of Washington, Depart-
ment of Medicine, Seattle, WA; 3. Puget Sound Oncology Consortium,
Seattle, WA.
Relapse remains a major problem after autologous stem cell
transplant for advanced breast cancer. GM-CSF has been shown in
vitro to enhance IL-2 mediated tumor lysis. We evaluated if the
addition of IL-2 and GM-CSF early after ASCT would reduce the
risk for relapse and prolong survival, Between April 1998 and April
2002, 50 patients with inﬂammatory stage IIIB (n  18) and
chemo-responsive stage IV (n  32) breast cancer were treated
with high dose Busulfan (12 mg/kg), melphalan (100 mg/m2), and
Thiotepa (500 mg/m2), followed by the infusion of autologous/
syngeneic peripheral blood stem ells (PBSC). Thirty to 100 days
after PBSC infusion after recovering from the acute toxicity of the
myeloablative therapy, patients were scheduled to receive 12 weeks
of IL-2 at 0.6  106 IU/m2 sc daily and GM-CSF 125 ug/m2 sc 3
times per week. All patients also took Tamoxifen 20 mg po qd
during the 12 weeks of immunotherapy. Twenty-six (52%) patients
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